Background Hepatitis C virus (HCV) is a major health issue worldwide. New generation of direct-active antiviral medications is an epoch-making turning point in the management of HCV infections. Objective Conducing a cost-effectiveness analysis comparing the combination of elbasvir/grazoprevir and sofosbuvir + pegylated interferon/ribavirin for the management of all HCV patients (even those in the initial stages of fibrosis). Methods A Markov model was built on the natural history of the disease to assess the efficacy of the alternatives. The outcomes are expressed in terms of quality adjusted life-years (QALYs) and result in terms of incremental cost-effectiveness ratio). Results Elbasvir/grazoprevir implies an expenditure of €21,104,253.74 with a gain of 19,287.90 QALYs and sofosbuvir + pegylated interferon/ribavirin implies an expenditure of €31,904,410.11 with a gain of 18,855.96 QALYs. Elbasvir/ grazoprevir is thus a dominant strategy. Conclusion Consideration should be given to the opportunity cost of not treating patients with a lower degree of fibrosis (F0-F2).
CITATION STYLE
Rolli, F. R., Ruggeri, M., Kheiraoui, F., Drago, C., Basile, M., Favaretti, C., & Cicchetti, A. (2018). Economic evaluation of zepatier for the management of HCV in the Italian scenario. European Journal of Health Economics, 19(9), 1365–1374. https://doi.org/10.1007/s10198-018-0980-4
Mendeley helps you to discover research relevant for your work.